Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice

International Journal of Obesity

Volumn 36, Issue 2, 2012, Pages 233-243

  Premaratna, S D ^a   Manickam, E ^b   Begg, D P ^a,b   Rayment, D J ^a   Hafandi, A ^a   Jois, M ^a   Cameron Smith, D ^b   Weisinger, R S ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

captopril; diet induced obesity; inflammation; insulin resistance

Indexed keywords

ADIPONECTIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; FATTY ACID SYNTHASE; HORMONE SENSITIVE LIPASE; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN LIPASE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PYRUVIC ACID; TOLL LIKE RECEPTOR 4; UNCOUPLING PROTEIN 2; WATER;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIET; ENZYME INHIBITION; FOOD INTAKE; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIVER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; CAPTOPRIL; CHEMOKINE CCL2; DIET, HIGH-FAT; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; ION CHANNELS; LEPTIN; LIPID METABOLISM; LIPOPROTEIN LIPASE; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; MUSCLE, SKELETAL; OBESITY; STEROL ESTERASE; TOLL-LIKE RECEPTOR 4; TRANS-ACTIVATORS;

ANIMALIA; MUS;

EID: 84857049090     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.95     Document Type: Article

References (58)

1. Hilzendeger AM, Morais RL, Todiras M, Plehm R, Goncalves AD, Nakaie CR et al. Leptin regulates ACE activity in mice. J Mol Med 2010; 88: 899-907.
2. Schelbert KB. Comorbidities of obesity. Prim Care 2009; 36: 271-285.
3. Nguyen MT, Favelyukis S, Nguyen AK, Reichart DD, Scott PA. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-35292. (Pubitemid 350232441)
4. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850. (Pubitemid 28496456)
5. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expressions of transforming growth factor-b in adipose tissue from obese mice. Mol Med 1997; 3: 37-48. (Pubitemid 27142523)
6. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-A in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
7. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56: 16-23.
8. Das UN. A perinatal strategy to prevent coronary heart disease. Nutrition 2002; 19: 1022-1027.
9. Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol 1993; 264: C1570-C1576. (Pubitemid 23198527)
10. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. Angiotensinogen levels and obesity in four black populations. J Hypertens 1998; 16: 571-575. (Pubitemid 28230544)
11. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
12. Jones BH, Standridge MK, Moustaid N. Angiotensin 11 increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997; 138: 1512-1519. (Pubitemid 27137101)
13. Goossens GH, Blaak EES, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 2004; 89: 2690-2696. (Pubitemid 38766351)
14. Chu KY, Leung PS. Angiotensin II in type 2 diabetes mellitus. Curr Protein Pept Sci 2009; 10: 75-84.
15. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. Angiotensin II induces gene transcription through cell-typedependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 2000; 212: 155-169.
16. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042-1048. (Pubitemid 350166045)
17. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23: 265-276.
18. Lv J, Jia R, Yang D, Zhu J, Ding G. Candesartan attenuates angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 2009; 380: 81-86.
19. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998; 16: 1789-1796. (Pubitemid 28548518)
20. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38: 884-890. (Pubitemid 34258687)
21. Higashiura K, Ura N, Takada T, Li Y, Torii T, Togashi N et al. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 2000; 2000: 290-297. (Pubitemid 30206952)
22. Weisinger RS, Stanley TK, Begg DP,Weisinger HS, Spark KJ, Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 2009; 98: 192-197.
23. Santos EL, de Picoli souza K, Guimarães PB, Reis FCG, Silva SMA, Costa-Neto CM et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol 2008; 8: 247-253.
24. de Kloet AD, Krause EG, Kim DH, Sakai RR, Seeley RJ, Woods SC. The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology 2009; 150: 4114-4123.
25. Albuquerque D, Nihei J, Cadillo F, Singh R. The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD25(negative) splenic T-cell numbers. Cell Immunol 2010; 260: 92-97.
26. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616. (Pubitemid 29087980)
27. Beevers DG, Weissberg PL, Thurston H, Bing RF, Breckenridge A, L'OrmeM et al. Enalapril in essential hypertension: A comparative study with propranolol. Enalapril in hypertension study group (UK). Br J Pharmacol 1984; 18: 51-56. (Pubitemid 14057122)
28. Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 2009; 48: 275-297.
29. Puigserver P, Spiegelman BM. Peroxisome proliferator-Activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator. Endocr Rev 2003; 24: 78-90. (Pubitemid 36223280)
30. Lazarow PB. Rat liver peroxisomes catalyze the b oxidation of fatty acids. J Biol Chem 1978; 253: 1522-1528. (Pubitemid 8303455)
31. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008; 105: 6531-6536. (Pubitemid 351754541)
32. Maffei M, Halaas JL, Ravussin E, Pratley RE, Lee GH, Zhang Yet al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161.
33. Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I. Peripheral, but not central, administration of adiponectin reduces visceral adiposity and up regulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 2003; 52: 2266-2273. (Pubitemid 37059496)
34. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529. (Pubitemid 38667912)
35. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S. Adiponectin stimulates glucose utilization and fatty-Acid oxidation by activating AMP-Activated protein kinase. Nat Med 2002; 8: 1288-1295. (Pubitemid 35373562)
36. Lihn AS, stergård T, Nyholm B, Pedersen SB, Richelsen B, Schmitz O. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003; 284: 443-448.
37. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T et al. Blockade of the angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724. (Pubitemid 44684802)
38. Hattori Y, Akimoto K, Gross S, Hattori S, Kasai K. Angiotensin-IIinduced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48: 1066-1074. (Pubitemid 40909640)
39. Suzuki H, Eguchi S. Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney Int 2006; 70: 1678-1679. (Pubitemid 44684797)
40. Kintscher U, Unger T. Vascular protection in diabetes: A pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005; 42: S26-S32.
41. Jayasooriya AP, Begg DP, Chen N, Mathai ML, Sinclair AJ, Wilkinson-Berka J et al. Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostagland Leukot Essent Fatty Acids 2008; 78: 67-72.
42. Weisinger HS, Begg DP, Egan GF, Jayasooriya AP, Lie F, Mathai ML et al. Angiotensin converting enzyme inhibition from birth reduces body weight and body fat in Sprague-Dawley rats. Physiol Behav 2008; 93: 820-825. (Pubitemid 351381081)
43. Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes 2008; 32: 1576-1584.
44. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449. (Pubitemid 24102039)
45. Weisinger RS, Denton DA, Di Nicolantonio R, McKinley MJ, Muller AF, Tarjan E. Role of angiotensin in sodium appetite of sodium-deplete sheep. Am J Physiol 1987; 253: R482-R488.
46. Mietlicki EG, Nowak EL, Daniels D. The effect of ghrelin on water intake during dipsogenic conditions. Physiol Behav 2009; 96: 37-43.
47. Pederson BA, Schroeder JM, Parker GE, SmithMW, DePaoli-Roach AA, Roach PJ. Glucose metabolism in mice lacking muscle glycogen synthase. Diabetes 2005; 54: 3466-3473. (Pubitemid 43334337)
48. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703. (Pubitemid 26145805)
49. De Fronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177-269. (Pubitemid 27453244)
50. Biddinger SB, Kahn CR. From mice to men: Insights into the insulin resistance syndromes. Annu Rev Physiol 2006; 68: 123-158.
51. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787. (Pubitemid 34000780)
52. Xinghai L, Bobby M, Qingyuan G, Morris JB. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1a transcription coactivator. Nature 2007; 47: 1038-1042.
53. Senn JJ, Klover PJ, Nowak IA, Zimmers TG, Koniaris LG, Furlanetto RW et al. Suppressor of cytokine signaling-3 (SCOCS-3), a potentialmediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740-13746. (Pubitemid 36799910)
54. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-1543.
55. Zhang CY, Baffy G, Perret P. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001; 105: 745-755. (Pubitemid 32635104)
56. Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-966. (Pubitemid 34020662)
57. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue: Implication of macrophages resident in the adipose tissue. J Clin Endocrinol Metab 2005; 90: 2282-2289. (Pubitemid 40586275)
58. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.